New study adds support, and caution, on grapiprant for canine OA

A newly published Frontiers in Veterinary Science study suggests grapiprant may reduce osteoarthritic pain and improve mobility in dogs with naturally occurring disease, while also shifting blood-based metabolic markers linked to inflammation. In the prospective off-on-off trial, published June 15, 2026, 36 dogs with mild to moderate OA completed 60 days of treatment at 2 mg/kg once daily, with investigators reporting improvement across owner questionnaires, gait assessment, and metabolomic profiling. (frontiersin.org)

That matters because grapiprant has been in the canine OA toolkit for a decade, yet questions about the strength of its evidence base haven't fully gone away. FDA approved Galliprant in March 2016 for control of pain and inflammation associated with osteoarthritis in dogs, based on field data supporting safety and effectiveness at 2 mg/kg once daily. The drug is a prostaglandin E2 EP4 receptor antagonist, positioned as a non-COX-inhibiting anti-inflammatory option. (animaldrugsatfda.fda.gov)

The new study adds a different kind of signal. Researchers screened 83 dogs, enrolled 42, and analyzed 36 that completed the protocol. The design included 30 days before treatment, 60 days on grapiprant, and 30 days after discontinuation. Outcomes included the Liverpool Osteoarthritis in Dogs score, Canine Brief Pain Inventory measures, gait lameness scoring on a pressure-sensitive walkway, orthopedic exams, and proton NMR-based plasma metabolomics. The authors reported no clinically relevant adverse effects during the study period. (frontiersin.org)

On the laboratory side, investigators found separation between pre- and post-treatment plasma samples, with decreases in lactate, N-acetyl glycoproteins, and formate, and an increase in citrate. The authors interpret those changes as consistent with reduced inflammatory activity and improved energy metabolism. They also describe the paper as the first canine OA grapiprant study to pair clinical outcomes with metabolomics, which could be relevant if the field moves toward more objective monitoring of treatment response. (frontiersin.org)

Still, the study doesn't close the case. Its own limitations are important: there was no control group, the sample size was small, follow-up was limited, and the authors acknowledge possible overfitting risk in multivariate analyses. That caution lines up with a 2026 Veterinary Evidence review, which concluded that the current literature offers weak evidence that grapiprant reduces osteoarthritic pain in dogs and said the available findings remain limited and inconsistent. The review points to some positive randomized trial data in chronic OA, but says more appropriate studies are still needed. (frontiersin.org)

Industry and guideline context helps explain why this matters in practice. The 2022 AAHA pain management guidelines include grapiprant among tier 1 pharmacologic options for chronic pain in dogs and note that it blocks the EP4 receptor while leaving prostaglandin production otherwise unaltered. More recent OA market attention has centered on newer options such as bedinvetmab, but grapiprant remains one of the established oral choices for clinicians trying to balance efficacy, comorbidities, monitoring needs, route of administration, and pet parent preferences within a multimodal plan. (aaha.org)

Why it matters: For veterinary professionals, the takeaway is less "grapiprant proven" than "grapiprant supported, with caveats." The new paper strengthens the biologic plausibility of response and offers encouraging real-world signals in naturally occurring OA, especially by combining subjective and objective measures. But the total evidence base still falls short of the kind of large, controlled, comparative dataset that would clearly define where grapiprant sits relative to other NSAIDs, monoclonal antibodies, rehabilitation, weight management, and combination care. In day-to-day practice, that means grapiprant is still best viewed as one tool in individualized OA management, especially when patient factors make mechanism, tolerability profile, or oral administration relevant. (frontiersin.org)

What to watch: The next meaningful step is better comparative evidence, including larger controlled trials, longer-duration safety and effectiveness data, and research that can identify responders versus non-responders. The Frontiers authors explicitly call for larger cohorts, longer treatment periods, and multi-omics work, which suggests the next phase may be less about whether grapiprant can work at all, and more about which dogs benefit most, how durable that benefit is, and how clinicians can measure it more objectively. (frontiersin.org)